Answers are grounded in this paper and cite their sources.
AIMS: Automated insulin delivery (AID) systems are increasingly used in type 1 diabetes (T1D) management, yet large-scale real-world evidence in pediatric populations remains limited. This study assessed the impact of AID therapy on glycemic outcomes in children and adolescents with T1D using data from the international SWEET registry. METHODS: We performed an observational comparative study using two treatment periods (12 months before and after AID initiation). Data were obtained from the SWEET database, with 53 centers across 29 countries contributing eligible cases. Participants were children and adolescents (≤18 years) with T1D who initiated AID therapy between 2014 and 2022. Primary endpoints included HbA1c, mean sensor glucose, and percentages of time spent in predefined glycemic ranges. RESULTS: A total of 2,170 participants were included. AID therapy was associated with significant improvements in glycemic control. Time in the target range (70-180 mg/dL) and tight target range (70-140 mg/dL) increased, while mean sensor glucose and glucose variability decreased. Time below range (<70 mg/dL) was reduced. HbA1c improved without a significant change in total daily insulin dose. CONCLUSIONS: In this large multinational real-world cohort, AID therapy significantly improved glycemic outcomes and reduced hypoglycemia in children and adolescents with T1D. These findings support the effectiveness of AID systems across diverse clinical settings and underscore their value in pediatric diabetes care.
No takes yet. Share an insight, caveat, or question.
Seget et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: